Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1167 with Abiraterone and Prednisone in Metastatic Prostate Cancer
NCT06689163Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of M9466 in Metastatic Prostate Cancer (mPC), sponsored by Hengrui. Primary endpoints: Dose limiting toxicity at 28 days, Recommended phase II dose at 28 days and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
M9466
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06689163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689163.